Journal of Occupational
Health and Epidemiology
Rafsanjan university Of medical sciences
Volume 14, Issue 1 (Winter 2025)
J Occup Health Epidemiol 2025, 14(1): 24-30 |
Back to browse issues page
Ethics code: IR.SUMS.REC.1399.772
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Azarbakhsh H, Maleki Z, Dehghani S P, Jafari F, Zeighami S, Mirahmadizadeh A. Prostate Cancer in Southern Iran: The 16-year Mortality and Years of Life Lost from 2004 to 2019. J Occup Health Epidemiol 2025; 14 (1) :24-30
URL: http://johe.rums.ac.ir/article-1-861-en.html
URL: http://johe.rums.ac.ir/article-1-861-en.html
Related article in
Google Scholar
Google Scholar
Similar articles
Habibollah Azarbakhsh1 
, Zahra Maleki2 , Seyed Parsa Dehghani3 , Fatemeh Jafari2 , Shahryar Zeighami4 , Alireza Mirahmadizadeh *5
, Zahra Maleki2 , Seyed Parsa Dehghani3 , Fatemeh Jafari2 , Shahryar Zeighami4 , Alireza Mirahmadizadeh *5
1- Ph.D. in Epidemiology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
2- Ph.D. in Epidemiology, Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
3- Medical Doctor, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
4- Associate Prof., Dept. of Urology, School of Medicine, Shahid Faghihi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.
5- Associate Prof., Non-Communicable Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. ,mirahmadia@sums.ac.ir
2- Ph.D. in Epidemiology, Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
3- Medical Doctor, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
4- Associate Prof., Dept. of Urology, School of Medicine, Shahid Faghihi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.
5- Associate Prof., Non-Communicable Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. ,
Article history
Received: 2024/05/25
Accepted: 2024/11/15
ePublished: 2025/03/29
Accepted: 2024/11/15
ePublished: 2025/03/29
Subject:
Epidemiology
Abstract: (283 Views)
Background: As of 2020, prostate cancer is the fifth most common cause of fatalities due to cancer in males and is also the second most common type of cancer overall. The purpose of this study was to look into the patterns of prostate cancer-related mortality and years of life lost (YLL) in the province of Fars.
Materials and Methods: Data on all prostate cancer-related fatalities in the province of Fars were gathered for this cross-sectional investigation via the electronic population-based death registration system (EDRS). We calculated the crude mortality rate, age-standardized mortality rate (ASMR), years of life lost (YLL), and YLL rate. The JoinPoint Regression method was used to analyze the patterns over time.
Results: During the 16-year study period from 2004 to 2019, there were 1,836 deaths from prostate cancer in Fars province. The crude and standardized mortality rates showed an increasing trend over this period. The total number of years of life lost (YLL) due to prostate cancer during these 16 years was 15,785. The highest number of YLL occurred in the age group of 70-79 years, while the lowest was observed in individuals under 30. According to join point regression analysis, the YLL rate due to premature mortality increased over the 16 years, with an annual percent change (APC) of 2.3% (95% CI 0.2 to 4.4, p=0.034).
Conclusion: Prostate cancer-related death and YLL are on the rise, according to the study's findings. Therefore, it is necessary to improve diagnostic and therapeutic measures; more studies in this field are also recommended.
Materials and Methods: Data on all prostate cancer-related fatalities in the province of Fars were gathered for this cross-sectional investigation via the electronic population-based death registration system (EDRS). We calculated the crude mortality rate, age-standardized mortality rate (ASMR), years of life lost (YLL), and YLL rate. The JoinPoint Regression method was used to analyze the patterns over time.
Results: During the 16-year study period from 2004 to 2019, there were 1,836 deaths from prostate cancer in Fars province. The crude and standardized mortality rates showed an increasing trend over this period. The total number of years of life lost (YLL) due to prostate cancer during these 16 years was 15,785. The highest number of YLL occurred in the age group of 70-79 years, while the lowest was observed in individuals under 30. According to join point regression analysis, the YLL rate due to premature mortality increased over the 16 years, with an annual percent change (APC) of 2.3% (95% CI 0.2 to 4.4, p=0.034).
Conclusion: Prostate cancer-related death and YLL are on the rise, according to the study's findings. Therefore, it is necessary to improve diagnostic and therapeutic measures; more studies in this field are also recommended.
Keywords: Prostate Cancer [MeSH], Mortality Rate [MeSH], Years of Life Lost [MeSH], Regression [MeSH], Iran [MeSH]
References
1. Matthews HK, Bertoli C, de Bruin RAM. Cell cycle control in cancer. Nat Rev Mol Cell Biol. 2022;23(1):74-88. [DOI] [PMID]
2. Omram AR. The epidemiologic transition: a theory of the epidemiology of population change. 1971. Bull World Health Organ. 2001;79(2):161-70. [PMID] [PMCID]
3. Azarbakhsh H, Rezaei F, Dehghani SS, Hassanzadeh J, Janfada M, Mirahmadizadeh A. Trend Analysis of Lung Cancer Mortality and Years of Life Lost (YLL) in South of Iran, 2004-2019. Iran J Public Health. 2024;53(1):238-45. [DOI] [PMID] [PMCID]
4. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. [DOI] [PMID]
5. Guzman-Esquivel J, Murillo-Zamora E, Ortiz-Mesina M, Galvan-Salazar HR, De-Leon-Zaragoza L, Casarez-Price JC, et al. Regional and national burden of prostate cancer: incidence, mortality, years of life lost, and disability-adjusted life years, in Mexico and Latin America from 1990 to 2019. Int Urol Nephrol. 2023;55(9):2155-60. [DOI] [PMID] [PMCID]
6. Bray F, Piñeros M. Cancer patterns, trends and projections in Latin America and the Caribbean: a global context. Salud Publica Mex. 2016;58(2):104-17. [DOI] [PMID]
7. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61(6):1079-92. [DOI] [PMID]
8. Tsodikov A, Gulati R, Heijnsdijk EAM, Pinsky PF, Moss SM, Qiu S, et al. Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. Ann Intern Med. 2017;167(7):449-55. [DOI] [PMID] [PMCID]
9. Rafiemanesh H, Rajaei-Behbahani N, Khani Y, Hosseini S, Pournamdar Z, Mohammadian-Hafshejani A, et al. Incidence Trend and Epidemiology of Common Cancers in the Center of Iran. Glob J Health Sci. 2015;8(3):146-55. [DOI] [PMID] [PMCID]
10. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. [DOI] [PMID]
11. Withrow D, Pilleron S, Nikita N, Ferlay J, Sharma S, Nicholson B, et al. Current and projected number of years of life lost due to prostate cancer: A global study. Prostate. 2022;82(11):1088-97. [DOI] [PMID] [PMCID]
12. Shafiee G, Mousavian AH, Sheidaei A, Ebrahimi M, Khatami F, Gohari K, et al. The 15-year national trends of genital cancer incidence among Iranian men and women; 2005–2020. BMC Public Health. 2023;23(1):495. [DOI] [PMID] [PMCID]
13. Mirzaei M, Mirzadeh M, Mirzaei M. Mortality Rate and Years of Life Lost Due to Prostate Cancer in Yazd Province, Iran: A 10-year study. Sultan Qaboos Uni Med J. 2017;17(4):e424-9. [DOI] [PMID] [PMCID]
14. Askari Tajabadi N, Pakmanesh H, Mirzaee M, Jahani Y. The Evaluation of Survival Rate in Patients with Prostate Cancer by Bayesian Weibull Parametric Accelerated Failure-Time Model. Iran J Public Health. 2022;51(9):2108-16. [DOI] [PMID] [PMCID]
15. Mirahmadizadeh A, Vali M, Hassanzadeh J, Dehghani SP, Razeghi A, Azarbakhsh H. Mortality Rate and Years of Life Lost due to Hypertension in the South of Iran between 2004 and 2019: A Population-Based Study. Int J Hypertens. 2022;2022:7759699. [DOI] [PMID] [PMCID]
16. Azarbakhsh H, Sharifi MH, Hassanzadeh J, Dewey RS, Janfada M, Mirahmadizadeh A. Diabetes in southern Iran: a 16-year follow-up of mortality and years of life lost. Int J Diabetes Dev Ctries. 2023;43:574-80. [DOI]
17. Dragomirescu I, Llorca J, Gómez-Acebo I, Dierssen-Sotos T. A join point regression analysis of trends in mortality due to osteoporosis in Spain. Sci Rep. 2019;9(1):4264. [DOI] [PMID] [PMCID]
18. Mirahmadizadeh A, Moftakhar L, Dehghani SS, Hassanzadeh J, Dehghani SP, Azarbakhsh H. Mortality Rate and Years of Life Lost Due to Burns in Southern Iran During 2004–2019: A Population-Based Study. Arch Iran Med. 2023;26(4):205-11. [DOI] [PMID] [PMCID]
19. Hassanipour S, Fathalipour M, Salehiniya H. The incidence of prostate cancer in Iran: a systematic review and meta-analysis. Prostate Int. 2018;6(2):41-5. [DOI] [PMID] [PMCID]
20. López JF, Fernández MI, Coz F. Prostate cancer mortality trends in Chile (1955-2019). Rev Med Chil. 2022;150(10):1370-9. [DOI] [PMID]
21. Rencsok E, Sodipo M, Gerke T, Stopsack K, Mucci L. Abstract 38: Racial disparities in prostate cancer mortality rates explained by differences in dietary and lifestyle factors. Cancer Res. 2022;82(12_Supplement):38. [DOI]
22. Rafimanesh H, Ghoncheh M, Salehinia H, Mohammadian Hafashjani A. Epidemiology of prostate cancer and its incidence trends in Iran. J Sabzevar Uni Med Sci. 2016;23(2):320-7. [URL]
23. Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, Seddighi Z. Cancer incidence and mortality in Iran. Ann Oncol. 2009;20(3):556-63. [DOI] [PMID]
24. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008. Int J Cancer. 2010;127(12):2893-917. [DOI] [PMID]
26. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. [DOI] [PMID]
27. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-49. [DOI] [PMID]
28. Okebugwu PN, Ayeni ET, Okebugwu PC, Kolawole EO. Aging: a systematic review on the correlation between geriatric diseases and prostate cancer. Agrobiol Rec. 2023;11:55-66. [DOI]
29. Fischer-Valuck BW, Baumann BC, Brown SA, Filson CP, Weiss A, Mueller R, et al. Treatment patterns and overall survival outcomes among patients aged 80 yr or older with high-risk prostate cancer. Eur Urol Open Sci. 2022;37:80-9. [DOI] [PMID] [PMCID]
30. Farhood B, Geraily G, Alizadeh A. Incidence and mortality of various cancers in Iran and compare to other countries: a review article. Iran J Public Health. 2018;47(3):309-16. [PMID] [PMCID]
31. Pakzad R, Mohammadian-Hafshejani A, Ghoncheh M, Pakzad I, Salehiniya H. The incidence and mortality of prostate cancer and its relationship with development in Asia. Prostate Int. 2015;3(4):135-40. [DOI] [PMID] [PMCID]
32. Pakzad R, Rafiemanesh H, Ghoncheh M, Sarmad A, Salehiniya H, Hosseini S, et al. Prostate cancer in Iran: trends in incidence and morphological and epidemiological characteristics. Asian Pac J Cancer Prev. 2016;17(2):839-43. [DOI] [PMID]
33. Torres‐Roman JS, Ruiz EF, Martinez‐Herrera JF, Mendes Braga SF, Taxa L, Saldaña‐Gallo J, et al. Prostate cancer mortality rates in Peru and its geographical regions. BJU Int. 2019;123(4):595-601. [DOI] [PMID]
34. Withrow D, Pilleron S, Nikita N, Ferlay J, Sharma S, Nicholson B, et al. Current and projected number of years of life lost due to prostate cancer: A global study. Prostate. 2022;82(11):1088-97. [DOI] [PMID] [PMCID]
35. Burnet NG, Jefferies SJ, Benson RJ, Hunt DP, Treasure FP. Years of life lost (YLL) from cancer is an important measure of population burden—and should be considered when allocating research funds. Br J Cancer. 2005;92(2):241-5. [DOI] [PMID] [PMCID]
36. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19(8):1893-907. [DOI] [PMID]
37. Bouchardy C, Fioretta G, Rapiti E, Verkooijen HM, Rapin CH, Schmidlin F, et al. Recent trends in prostate cancer mortality show a continuous decrease in several countries. Int J Cancer. 2008;123(2):421-9. [DOI] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution 4.0 International License. |
